A Randomized, Double-Blind, Placebo-Controlled Trial to Examine the Effectiveness of Lubiprostone on Constipation Symptoms and Colon Transit Time in Diabetic Patients

American Journal of Gastroenterology

Volumn 112, Issue 2, 2017, Pages 356-364

  Christie, Jennifer ^a   Shroff, Sagar ^a   Shahnavaz, Nikrad ^a   Carter, Latoya A ^a   Harrison, Melanie S ^a,b   Dietz Lindo, Karan A ^a   Hanfelt, John ^c   Srinivasan, Shanthi ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LUBIPROSTONE; PLACEBO; CHLORIDE CHANNEL STIMULATING AGENT;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; BLOATING; CAPSULE ENDOSCOPY; CHRONIC CONSTIPATION; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DIABETIC PATIENT; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; IDIOPATHIC DISEASE; INTESTINE TRANSIT TIME; MAJOR CLINICAL STUDY; MALE; MOTILITY CAPSULE; MULTICENTER STUDY; NAUSEA; OUTPATIENT DEPARTMENT; PATIENT ASSESSMENT OF CONSTIPATION QUALITY OF LIFE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TERTIARY CARE CENTER; TREATMENT DURATION; VERY ELDERLY; VOMITING; COLON; COMPLICATION; CONSTIPATION; DEFECATION; GASTROINTESTINAL TRANSIT; INSULIN DEPENDENT DIABETES MELLITUS; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; QUALITY OF LIFE; QUESTIONNAIRE; TREATMENT OUTCOME;

AGED; CHLORIDE CHANNEL AGONISTS; COLON; CONSTIPATION; DEFECATION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL TRANSIT; HUMANS; LUBIPROSTONE; MALE; MIDDLE AGED; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 85001755059     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.531     Document Type: Article

References (24)

1. National Center for Chronic Disease Prevention and Health Promotion, Division of Diabetes Translation. cdc.gov.website 2014.
2. Enck P, Rathmann W, Spiekermann M et al. Prevalence of gastrointestinal symptoms in diabetic patients and non-diabetic subjects. Z Gastroenterol 1994; 32: 637-41.
3. Sharma S, Longo WE, Baniadam B et al. Colorectal manifestations of endocrine disease. Dis Colon Rectum 1995; 38: 318-23.
4. Drossman DA. The functional gastrointestinal disorders and the Rome II process. Gut 1999; 45 Suppl 2: II1-II5.
5. Battle WM, Snape WJ Jr, Alavi A et al. Colonic dysfunction in diabetes mellitus. Gastroenterology 1980; 79: 1217-21.
6. Celik AF, Osar Z, Damci T et al. How important are the disturbances of lower gastrointestinal bowel habits in diabetic outpatients? Am J Gastroenterol 2001; 96: 1314-6.
7. Chandrasekharan B, Anitha M, Blatt R et al. Colonic motor dysfunction in human diabetes is associated with enteric neuronal loss and increased oxidative stress. Neurogastroenterol Motil 2011; 23: 131-138, e126.
8. Yarandi SS, Srinivasan S. Diabetic gastrointestinal motility disorders and the role of enteric nervous system: current status and future directions. Neurogastroenterol Motil 2014; 26: 611-24.
9. Talley NJ, Young L, Bytzer P et al. Impact of chronic gastrointestinal symptoms in diabetes mellitus on health-related quality of life. Am J Gastroenterol 2001; 96: 71-6.
10. Dordaneh Maleki CM, Burton DD. Pilot study of pathophysiology of constipation among community diabetics. Dig Dis Sci 1998; 43: 2373-8.
11. Lembo AJ, Johanson JF, Parkman HP et al. Long-term safety and Effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation. Dig Dis Sci 2011; 56: 2639-45.
12. Johanson JF, Drossman DA, Panas R et al. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008; 27: 685-96.
13. Johanson JF, Morton D, Geenen J et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol 2008; 103: 170-7.
14. Cassilly D, Kantor S, Knight LC et al. Gastric emptying of a non-digestible solid: assessment with simultaneous SmartPill pH and pressure capsule, antroduodenal manometry, gastric emptying scintigraphy. Neurogastroenterol Motil 2008; 20: 311-9.
15. Rao SS, Kuo B, McCallum RW et al. Investigation of colonic and whole-gut transit with wireless motility capsule and radiopaque markers in constipation. Clin Gastroenterol Hepatol 2009; 7: 537-44.
16. Maqbool S, Parkman HP, Friedenberg FK. Wireless capsule motility: comparison of the SmartPill GI monitoring system with scintigraphy for measuring whole gut transit. Dig Dis Sci 2009; 54: 2167-74.
17. Marquis P, De La Loge C, Dubois D et al. Development and validation of the patient assessment of constipation quality of life questionnaire. Scand J Gastroenterol 2005; 40: 540-51.
18. Camilleri M, Bharucha AE, Ueno R et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2006; 290: G942-G947.
19. Barish CF, Drossman D, Johanson JF et al. Efcacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci 2010; 55: 1090-7.
20. Camilleri M, Torne NK, Ringel Y et al. Wireless pH-motility capsule for colonic transit: prospective comparison with radiopaque markers in chronic constipation. Neurogastroenterol Motil 2010; 22: 874-882, e233.
21. Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efcacy and safety. Aliment Pharmacol Ther 2007; 25: 1351-61.
22. Jiao HY, Kim DH, Ki JS et al. Effects of lubiprostone on pacemaker activity of interstitial cells of cajal from the mouse colon. Korean J Physiol Pharmacol 2014; 18: 341-6.
23. Fukudo S, Hongo M, Kaneko H et al. Lubiprostone increases spontaneous bowel movement frequency and quality of life in patients with chronic idiopathic constipation. Clin Gastroenterol Hepatol 2015; 13: 294-301 e295.
24. Solem CT, Patel H, Mehta S et al. Treatment patterns, symptom reduction, quality of life, and resource use associated with lubiprostone in irritable bowel syndrome constipation subtype. Curr Med Res Opin 2016; 32: 1-33.